|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Rheumatoid Arthritis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Arthritis | |||||
| Arthritis, Rheumatoid | |||||
| 3 | More general conditions related to this trial | ||||
| Autoimmune Diseases | |||||
| Connective Tissue Diseases | |||||
| Immune System Diseases | |||||
| Joint Diseases | |||||
| Musculoskeletal Diseases | |||||
| Rheumatic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| adalimumab | |||||
| placebo | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Inflammatory Agents | |||||
| Antirheumatic Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Abbott | |||||
| Eisai Limited | |||||